Tricitrates
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Tricitrates
- Generic name
- TRICITRATES
- Manufacturer
- Chartwell RX, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 2a80ea6b-6334-4c33-a35e-a5cb2939fbcb
- SPL ID
- 33d7941b-0652-9528-e063-6394a90a8a55
- Version
- 6
- Effective date
- 2025-04-28
- Source export date
- 2026-09-28
- Source partition
- 2
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/f7d2b6e3f8600cd856280ab55a9c6fa54a642647191d164f9d1110e89f3f4097/drug-label-0002-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:15:19
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| brand name | Tricitrates | openfda.brand_name | |
| generic name | TRICITRATES | openfda.generic_name | |
| manufacturer name | Chartwell RX, LLC | openfda.manufacturer_name | |
| ndc | package | 62135-438-05 | openfda.package_ndc |
| ndc | package | 62135-438-47 | openfda.package_ndc |
| ndc | package | 62135-438-24 | openfda.package_ndc |
| ndc | product | 62135-438 | openfda.product_ndc |
| ndc11 | package | 62135043824 | derived:openfda.package_ndc |
| ndc11 | package | 62135043847 | derived:openfda.package_ndc |
| ndc11 | package | 62135043805 | derived:openfda.package_ndc |
| rxcui | 309317 | openfda.rxcui | |
| spl id | 33d7941b-0652-9528-e063-6394a90a8a55 | id | |
| spl set id | 2a80ea6b-6334-4c33-a35e-a5cb2939fbcb | set_id | |
| unii | 2968PHW8QP | openfda.unii | |
| unii | EE90ONI6FF | openfda.unii | |
| unii | 1Q73Q2JULR | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
PRECAUTIONS AND WARNINGS Should be used with caution by patients with low urinary output or reduced glomerular filtration rates unless under the supervision of a physician. Aluminum-based antacids should be avoided in these patients. Patients should be directed to dilute adequately with water and, preferably, to take each dose after meals, to minimize the possibility of gastrointestinal injury associated with oral ingestion of potassium salt preparations and to avoid saline laxative effect. Sodium salts should be used cautiously in patients with cardiac failure, hypertension, peripheral and pulmonary edema, and toxemia of pregnancy. Concurrent administration of potassium-containing medication, potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, or cardiac glycosides may lead to toxicity. Periodic examination and determinations of serum electrolytes, particularly serum bicarbonate level, should be carried out in those patients with renal disease in order to avoid these complications.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Tricitrates oral solution is generally well tolerated without any unpleasant side effects when given in recommended doses to patients with normal renal function and urinary output. However, as with any alkalinizing agent, caution must be used in certain patients with abnormal renal mechanisms to avoid development of hyperkalemia or alkalosis, especially in the presence of hypocalcemia. Potassium intoxication causes listlessness, weakness, mental confusion, and tingling of extremities.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.